Inmagene Signs $920 Million Agreement to Acquire Four Chi-Med Immunology Therapies
publication date: Jan 11, 2021
Shanghai's Inmagene in-licensed global rights to four novel pre-clinical immunological candidates from Hutchison China MediTech (Chi-Med) in a deal that has a potential value of $920 million. With funding from Inmagene, the two companies will work together to advance the molecules through IND submissions. Inmagene will be in charge of global clinical development. For each candidate, Inmagene will be responsible for up to $95 million in development milestones and $135 million in commercial payments, plus up to double-digit royalties. Founded in 2019, Inmagene has raised over $40 million. More details....
Stock Symbols: (NSDQ/AIM: HCM)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.